Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...EAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics In... in a randomized Phase 2B study of AEG35156, a tar...nt for multiple oncology indications. ,, The st...udy of the X-Linked Inhibitor of Apoptosis (XIAP) ...dose Cytarabine and Idarubicin in AML Following Fa...
(Date:11/19/2009)... VIENNA, Austria, November 19 AF...m on one product candidate at an unexpectedly earl... is planned to enter into,Phase II clinical trial ...ately follows the completion of two Phase I trials...sed its fast decision on the first interim,analysi...
(Date:11/18/2009)...ll. Imagine a polka-dotted postage stamp that can... by changing colors. , As reported in the Sept. ...h Suslick and his team at the University of Illino...al detection of toxic industrial chemicals (TICs) ... visualizing odors. This sensor array could be us...
(Date:11/18/2009)...E, Calif., Nov. 18 Mas...metry(TM) and Measure-Through Motion and Low-Perfu...ance-based Uni.H.A., one of the largest healthcare...as signed a multi-year purchasing agreement for "g... The agreement offers preferred contract pricing t...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4
..., December 11 , - New ,Trophon EPR, Device ...ultrasound transducer disinfection are in many cas...he latest alarming result,issued by the Center for... US,public health agency, in its recently publishe...Healthcare Facilities (1). The guideline is the CD...
...1 Delcath Systems, Inc. (Nasdaq: DCTH ), a me...ercutaneous Hepatic Perfusion ("PHP") System for t...day that the first fifty percent (46 of 92) of pat... trial treating metastatic cutaneous and ocular me...cer centers in this trial continue to evaluate and...
... Alimera Sciences Inc., a privately held,biopharm..., development and,commercialization of prescriptio...enrollment has begun for a pilot study to assess t...with bilateral geographic atrophy (GA) secondary t...The pilot study will compare two doses of Iluvien ...
Other Biology Technology:Ultrasound Transducer Disinfection in Many Cases Insufficient 2Ultrasound Transducer Disinfection in Many Cases Insufficient 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...2: The offspring of two inbred strains tend to be ...the gene-level variability that leads to this phen...boost our ability to custom-tailor crops for speci... consumption or high glucose content for biomass f...quence of the common corn strain B73, University o...
(Date:11/19/2009)...nable farming, initially adopted to preserve soil ...le in maintaining a healthy climate, according to ...e and Los Alamos national laboratories. , ORNL a...al of the earth,s soils to sequester carbon, with ...ld greatly reduce U.S. carbon emissions by as much...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 1Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 2Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 3Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 1Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 2Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 3Must Haves for Your Summer Vacation Bag 52922 1Must Haves for Your Summer Vacation Bag 52922 2Must Haves for Your Summer Vacation Bag 52922 3
...ma Barkai will receive the Helen and Martin Kimmel.... 5 at the Weizmann Institute. The award is accomp...r five years. , Taking a chance on an experiment ... Living cells are, from this angle, great subjects...have all sorts of interesting consequences for man...
...e in the November 2007 issue of BioScience describ...llenges of green roofsroofs with a vegetated surfa...struct than a typical roof, a green roof can reduc...trol storm-water runoff. Green roofs also provide ... less common in the United States than in Japan an...
... Far removed from streams of gas-thirsty cars and ...er in global climate change. Circling the norther... - one of the largest ecosystems on earth - act as...vels. , Forest ecologists at the University of Wi...tors such as forest fires and climate influence ca...
Other Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Wildfire drives carbon levels in northern forests 2
CORNING ROLLER BOTTLES, 850 CM2, PS, EASY GRIP CAP, STERILE from Sigma-Aldrich
...n be upgraded to the GenePix Autoloader 4200AL. Th...nalyzes, and saves results for up to 36 slides, th...e. Line-by-line autofocus ensures superior field u...es you complete flexibility to configure scanning ...
...rray data using Asuragens bioinformatics expertise...to extensive data analysis using the most up to da...ith the Gene Expression Profiling Service or from ...on and basic statistical analysis including public...
Illumina Custom Data Analysis Report from Asuragen, Inc.
Biology Products: